Mennander Ari, Kuukasjärvi Pekka, Laurikka Jari, Nikus Kjell, Karhunen Pekka J, Tarkka Matti, Lehtimäki Terho
Heart Center, Tampere University Hospital and Tampere University Medical School, Tampere, Finland.
Scand J Clin Lab Invest. 2008;68(8):714-9. doi: 10.1080/00365510802172145.
Plasma high sensitive C-reactive protein (hsCRP) concentration is an important clinical test of systemic inflammation and, like apoE epsilon4 allele, an important risk factor of coronary artery disease (CAD). We investigated whether the diagnostic performance of plasma hsCRP in detecting severe 3-vessel CAD may be modified by apoE epsilon4 carrier status.
The study population (Angiography and Genes Study) comprised 485 Finnish subjects (336 men and 149 women, mean age 64.0+/-1.0) undergoing coronary angiography. ApoE genotypes were determined by the PCR-based method and by hsCRP using an automatic analyser.
The diagnostic performance of hsCRP concentration in distinguishing 3-vessel CAD from its less widespread forms (non-3-vessel CAD) was assessed by receiver operating characteristic curve (ROC) analysis separately in apoE epsilon4 non-carriers and epsilon4 carriers. ROC analysis showed that hsCRP predicted 3-vessel CAD in apoE epsilon4 non-carriers (AUC 0.646; SE 0.035; p = 0.0001; 95 % CI 0.578-0.714) but not in epsilon4 carriers (AUC 0.518; SE 0.049; p = 0.719; 95 % CI 0.422-0.615). Multinomial logistic regression analysis revealed a significant (p<0.05) apoE epsilon4 group versus hsCRP group (<1.0 mg/L/>or=1.0 mg/L) interaction in relation to incidence of 3-vessel CAD. In apoE epsilon4 non-carriers, high hsCRP (>or=1.0 mg/L) was significantly (OR 2.1; 95 % CI 1.233-3.562; p = 0.006) associated with high incidence of 3-vessel CAD after adjustment for major CAD risk factors.
The diagnostic performance of hsCRP in distinguishing 3-vessel CAD from less extensive forms of coronary atherosclerosis is more accurate in a group of subjects without the apoE epsilon4 allele than in patients with it.
血浆高敏C反应蛋白(hsCRP)浓度是全身性炎症的一项重要临床检测指标,与载脂蛋白Eε4等位基因一样,是冠状动脉疾病(CAD)的一项重要危险因素。我们研究了载脂蛋白Eε4携带者状态是否会改变血浆hsCRP检测严重三支血管CAD的诊断效能。
研究人群(血管造影与基因研究)包括485名接受冠状动脉造影的芬兰受试者(336名男性和149名女性,平均年龄64.0±1.0岁)。采用基于聚合酶链反应的方法确定载脂蛋白E基因型,并使用自动分析仪检测hsCRP。
通过受试者操作特征曲线(ROC)分析分别评估了hsCRP浓度在区分载脂蛋白Eε4非携带者和ε4携带者中三支血管CAD与其较不广泛形式(非三支血管CAD)方面的诊断效能。ROC分析显示,hsCRP在载脂蛋白Eε4非携带者中可预测三支血管CAD(曲线下面积0.646;标准误0.035;p = 0.0001;95%置信区间0.578-0.714),但在ε4携带者中则不能(曲线下面积0.518;标准误0.049;p = 0.719;95%置信区间0.422-0.615)。多项逻辑回归分析显示,在三支血管CAD发生率方面,载脂蛋白Eε4组与hsCRP组(<1.0mg/L/>或 = 1.0mg/L)之间存在显著(p<0.05)交互作用。在载脂蛋白Eε4非携带者中,校正主要CAD危险因素后,高hsCRP(>或 = 1.0mg/L)与三支血管CAD的高发生率显著相关(比值比2.1;95%置信区间1.233-3.562;p = 0.006)。
在区分三支血管CAD与较不广泛形式的冠状动脉粥样硬化方面,hsCRP在一组没有载脂蛋白Eε4等位基因的受试者中的诊断效能比在有该等位基因的患者中更准确。